Trulive
臻于至善 亿万之重
An innovative platform focused on the R&D and manufacturing of cardiovascular devices
Contributing to Life and Health
Jiangsu Trulive Trulive Medtech Co., Ltd., founded in 2019 in Nantong, Jiangsu, is an innovative high-end medical device enterprise in China focusing on the cardiovascular field. Integrating R&D, production, sales, and technical services, we are deeply committed to the cardiovascular health track, dedicated to breaking the monopoly of imported technology and creating high-quality domestic cardiovascular diagnosis and treatment devices.
The company has three wholly-owned subsidiaries: Anhui Yipeng Co., Ltd., Jiangsu Polylive Medtech Co., Ltd., and Hangzhou Dawneo Medical Technology Co., Ltd., and has established a core R&D center in Shanghai. Our product line comprehensively covers core areas such as heart valves, coronary and peripheral vessels. Core pipelines include DeepQuake® Intravascular Shock Wave Balloon, NeoNova® Transcatheter Mitral Valve Clip, NeoBlazar® Transcatheter Tricuspid Valve Clip, and other innovative interventional products.
Structural Heart Disease
A domestic transcatheter tricuspid valve edge-to-edge repair (T-TEER) system, offering a new minimally invasive interventional treatment option for surgical high-risk patients with severe tricuspid regurgitation.。
News & Insights
Stay updated with Trulive's latest developments and industry insights
Trulive Completes New Round of Over 100 Million Yuan Series C Financing, Continuing to Strengthen Platform Layout in Cardiovascular Intervention
Trulive officially announced the completion of its Series C financing of hundreds of millions of yuan, jointly invested by Oriental Fortune Capital, Guoyuan Equity, Xiamen Industrial Investment/Venture Capital, and other institutions.
World First Post-Commercialization Implant! Professor Wang Yan's Team from Xiamen Cardiovascular Hospital Performs the First Post-Launch T-TEER with NeoBlazar®, Successfully Treating an 86-Year-Old Patient with Severe Tricuspid Regurgitation
Recently, the team led by Professor Wang Yan from the Cardiovascular Hospital of Xiamen University overcame the challenges of this complex elderly case and performed the first post-launch transcatheter tricuspid edge-to-edge repair (T-TEER) using the NeoBlazar® tricuspid clip system.
Trulive Medical Launches NeoBlazar® Transcatheter Edge-to-Edge Repair System, Marking the New Domestic Era for Tricuspid Interventional Therapy
Recently, Jiangsu Trulive Medtech Co., Ltd. announced the official NMPA approval for its self-developed NeoBlazar® Transcatheter Tricuspid Clip System (Registration No.: NMPA 20263131494).
New Milestone in Global Footprint! Xiamen Heart Center Supports Domestic Mitral Clip System's Successful Entry into Argentina
Recently, the NeoNova® transcatheter mitral clip system, independently developed in China, has accelerated its overseas clinical deployment with support from the Cardiovascular Hospital of Xiamen University.
Double List Honors! Trulive Medical Named to Future Healthcare 100 List Again, Dual Rankings Demonstrate Solid Innovation Capabilities
Recently, the 2026 Future Healthcare & Pharmaceutical 100 Summit, co-hosted by VB Data together with 142 innovative medical and pharmaceutical enterprises, investment institutions, industrial parks and medical institutions, grandly opened in Shanghai.
Chinese Valves for the World | Xiamen Heart Center Team Supports Domestic Self-Developed Mitral Clip in First Batch Overseas Clinical Procedures in Chile
Recently, the NeoNova® transcatheter mitral clip system, independently developed in China, successfully completed its first two overseas clinical cases at the Hospital del Tórax Instituto Nacional del Tórax (National Thoracic Institute of Chile).